eli lilly retatrutide study Lilly's triple agonist hits 28.3% mean weight loss in TRIUMPH-1 phase 3, blowing past tirzepatide benchmarks & rewriting obesity math for payers, PBMs & the Novo Duopoly Today, we shared new data

References: Wilding JPH, Batterham RL, Calanna S, et al

In this context, the data currently available on tirzepatide, showing its efficacy in glycemic control to the extent that a considerable percentage of patients achieve glucose levels indicative of diabetes remission [3, 59], as well as its high effectiveness in weight management, are promising regarding its future use in clinical practice

In lean Ossaba swine, systemic infusion of GLP-1(736) showed no cardiometabolic or hemodynamic effects prior to ischemia, but it increased cardiac output by approximately 2 L/min relative to vehicle controls during ischemia (39)

The real fat loss builds over the following weeks and months